Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 12.62 percent. This is a 18.18 percent increase over losses of $(0.11) per share from the same period last year.